Syrna Therapeutics, Inc.
Syrna Therapeutics is pioneering a new class of mRNA targeting therapeutics that stop expression of disease-causing proteins
Funding history
About Syrna Therapeutics, Inc.
How much funding has Syrna Therapeutics, Inc. raised?
Syrna Therapeutics, Inc. has raised $10.9M in total funding. The most recent round was Series B.
Where is Syrna Therapeutics, Inc. headquartered?
Syrna Therapeutics, Inc. is headquartered in Del Mar, CA.
What does Syrna Therapeutics, Inc. do?
Syrna Therapeutics is pioneering a new class of mRNA targeting therapeutics that stop expression of disease-causing proteins
What problem does Syrna Therapeutics, Inc. solve?
mRNA is described as an untapped class of small-molecule drug targets because, unlike proteins, structure-guided drug discovery has not been applied to mRNA, leaving disease-causing proteins hard to shut down at the translation stage.
What's Syrna Therapeutics, Inc.'s solution?
Syrna develops covalent small-molecule 'translation inhibitors' that bind and chemically modify specific structured domains in the mRNA of disease-causing proteins, blocking the ribosome and preventing the protein from being made.
What makes Syrna Therapeutics, Inc. different?
The company states it is the first mRNA-focused, 3D structure-guided drug discovery company, using a proprietary platform to reveal the actual 3D structure of mRNA binding sites, and says its inhibition mechanism works independently of each target's underlying biology, making it broadly applicable across disease areas.
What makes Syrna Therapeutics, Inc. notable?
Founded by David Weitz, the biotech has raised $10.9M from investors including Innovation Endeavors and Insight Partners.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.